MCQ Quiz: Pharmacology of Selected Anti-inflammatory Agents: Azathioprine

Azathioprine is a cornerstone immunomodulator used in the management of complex inflammatory conditions, most notably Inflammatory Bowel Disease (IBD). Its pharmacology serves as a classic example of the intricate relationship between prodrug metabolism, pharmacogenomics, and clinically significant drug interactions, a topic explored in depth in the Patient Care 4 curriculum. A pharmacist’s understanding of azathioprine is critical for patient safety, requiring vigilance in monitoring, knowledge of the TPMT enzyme, and patient counseling. This quiz will test your comprehension of this important anti-inflammatory agent.

1. Azathioprine exerts its immunosuppressive effect by first being converted to which active compound?

  • a. Allopurinol
  • b. 6-mercaptopurine (6-MP)
  • c. Thiouric acid
  • d. Mesalamine

Answer: b. 6-mercaptopurine (6-MP)

2. The active metabolites of azathioprine, thioguanine nucleotides (TGNs), work by what mechanism?

  • a. They inhibit TNF-alpha.
  • b. They incorporate into DNA and RNA, disrupting lymphocyte proliferation.
  • c. They block the H+/K+ ATPase pump.
  • d. They antagonize histamine-2 receptors.

Answer: b. They incorporate into DNA and RNA, disrupting lymphocyte proliferation.

3. Azathioprine is best described as a:

  • a. Biologic agent
  • b. Prodrug
  • c. Stool softener
  • d. Saline laxative

Answer: b. Prodrug

4. A patient deficient in the enzyme Thiopurine S-methyltransferase (TPMT) is at a very high risk for what severe, life-threatening toxicity when taking azathioprine?

  • a. Hepatotoxicity
  • b. Nephrotoxicity
  • c. Myelosuppression (bone marrow suppression)
  • d. Cardiotoxicity

Answer: c. Myelosuppression (bone marrow suppression)

5. What is the recommended action before initiating azathioprine therapy to mitigate toxicity risk?

  • a. Administer a test dose.
  • b. Check the patient’s blood pressure.
  • c. Perform TPMT genotype or phenotype testing.
  • d. Obtain a baseline ECG.

Answer: c. Perform TPMT genotype or phenotype testing.

6. A patient who is a TPMT “poor metabolizer” should receive what dose of azathioprine?

  • a. A higher dose than standard.
  • b. The standard dose.
  • c. A drastically reduced dose or avoid the drug altogether.
  • d. A loading dose followed by a standard dose.

Answer: c. A drastically reduced dose or avoid the drug altogether.

7. A patient stabilized on azathioprine is newly prescribed allopurinol for gout. What is the concern with this combination?

  • a. Allopurinol will decrease the effectiveness of azathioprine.
  • b. Allopurinol inhibits xanthine oxidase, a key enzyme in azathioprine metabolism, leading to a high risk of severe toxicity.
  • c. The combination increases the risk of GERD.
  • d. There is no significant interaction.

Answer: b. Allopurinol inhibits xanthine oxidase, a key enzyme in azathioprine metabolism, leading to a high risk of severe toxicity.

8. If a patient must take allopurinol and azathioprine concurrently, the azathioprine dose should typically be:

  • a. Increased by 50%.
  • b. Doubled.
  • c. Reduced by approximately 66-75%.
  • d. Switched to every other day.

Answer: c. Reduced by approximately 66-75%.

9. What is the primary role of azathioprine in the management of Inflammatory Bowel Disease (IBD)?

  • a. For rapid induction of remission in an acute flare.
  • b. As a first-line agent for mild disease.
  • c. For maintaining remission and as a steroid-sparing agent.
  • d. For treating extra-intestinal manifestations only.

Answer: c. For maintaining remission and as a steroid-sparing agent.

10. How long does it typically take for azathioprine to exert its full therapeutic effect in IBD?

  • a. 24-48 hours
  • b. 1-2 weeks
  • c. 3-6 months
  • d. Immediately upon administration.

Answer: c. 3-6 months

11. The pharmacology of azathioprine is a specific topic within the Patient Care 4 curriculum.

  • a. True
  • b. False

Answer: a. True

12. Which of the following lab parameters must be monitored regularly in a patient taking azathioprine?

  • a. Serum electrolytes
  • b. Blood glucose
  • c. Complete Blood Count (CBC) with differential and Liver Function Tests (LFTs)
  • d. International Normalized Ratio (INR)

Answer: c. Complete Blood Count (CBC) with differential and Liver Function Tests (LFTs)

13. Azathioprine is an analog of which endogenous purine?

  • a. Adenine
  • b. Guanine
  • c. Xanthine
  • d. Hypoxanthine

Answer: b. Guanine

14. A patient on azathioprine develops a fever and a severe sore throat. The pharmacist should recognize this as a potential sign of:

  • a. An expected therapeutic effect.
  • b. Myelosuppression (specifically, leukopenia).
  • c. Pancreatitis.
  • d. A common, mild side effect.

Answer: b. Myelosuppression (specifically, leukopenia).

15. Besides TPMT, genetic variations in which other enzyme have been associated with thiopurine intolerance, especially in Asian populations?

  • a. NUDT15
  • b. CYP2C9
  • c. UGT1A1
  • d. SLCO1B1

Answer: a. NUDT15

16. Which of the following is NOT a potential long-term risk of azathioprine therapy?

  • a. Increased risk of non-Hodgkin lymphoma.
  • b. Increased risk of non-melanoma skin cancer.
  • c. Increased risk of infection.
  • d. Increased risk of hypertension.

Answer: d. Increased risk of hypertension.

17. The medicinal chemistry of azathioprine is a topic covered in the Patient Care 4 curriculum.

  • a. True
  • b. False

Answer: a. True

18. Why is azathioprine considered a “steroid-sparing” agent?

  • a. It has the same mechanism of action as steroids.
  • b. It allows for the dose of chronic corticosteroids to be reduced or discontinued while maintaining disease remission.
  • c. It increases the metabolism of steroids.
  • d. It prevents all side effects of steroids.

Answer: b. It allows for the dose of chronic corticosteroids to be reduced or discontinued while maintaining disease remission.

19. A common GI side effect that can occur when initiating azathioprine is:

  • a. Constipation
  • b. Nausea and vomiting
  • c. Black stools
  • d. Heartburn

Answer: b. Nausea and vomiting

20. A patient with normal TPMT activity will primarily metabolize 6-mercaptopurine via which two pathways?

  • a. TPMT and Xanthine Oxidase (XO)
  • b. HGPRT and UGT1A1
  • c. CYP3A4 and CYP2D6
  • d. Aldehyde dehydrogenase and alcohol dehydrogenase

Answer: a. TPMT and Xanthine Oxidase (XO)

21. The management of Inflammatory Bowel Disease is an active learning session in the Patient Care 4 course.

  • a. True
  • b. False

Answer: a. True

22. Azathioprine can be classified as a(n):

  • a. Antimetabolite
  • b. Alkylating agent
  • c. Topoisomerase inhibitor
  • d. Monoclonal antibody

Answer: a. Antimetabolite

23. A patient with Crohn’s Disease is in remission on infliximab and azathioprine. This is an example of:

  • a. Monotherapy
  • b. Combination therapy
  • c. Induction therapy
  • d. Palliative therapy

Answer: b. Combination therapy

24. The active thioguanine nucleotides (TGNs) are structurally similar to which natural purines, allowing them to be incorporated into DNA/RNA?

  • a. Cytosine and Thymine
  • b. Guanine and Adenine
  • c. Uracil
  • d. All of the above

Answer: b. Guanine and Adenine

25. A pharmacist’s role in managing azathioprine therapy includes:

  • a. Verifying the appropriateness of the dose based on TPMT status.
  • b. Counseling the patient on the need for routine lab monitoring.
  • c. Screening for the allopurinol drug interaction.
  • d. All of the above.

Answer: d. All of the above.

26. Why isn’t azathioprine effective for treating an acute flare of IBD?

  • a. Because of its slow onset of action.
  • b. Because it is not an anti-inflammatory drug.
  • c. Because it cannot be given orally.
  • d. Because it has too many side effects.

Answer: a. Because of its slow onset of action.

27. In a patient with zero TPMT activity, the 6-mercaptopurine is shunted towards which metabolic pathway?

  • a. The xanthine oxidase pathway, producing more thiouric acid.
  • b. The HGPRT pathway, producing dangerously high levels of active TGNs.
  • c. The CYP3A4 pathway.
  • d. It is not metabolized and is excreted unchanged.

Answer: b. The HGPRT pathway, producing dangerously high levels of active TGNs.

28. A key counseling point for a patient starting azathioprine is to immediately report:

  • a. Mild fatigue
  • b. Signs of infection, such as fever or chills.
  • c. Occasional headache
  • d. Decreased appetite

Answer: b. Signs of infection, such as fever or chills.

29. Febuxostat is another xanthine oxidase inhibitor used for gout. What interaction would you expect with azathioprine?

  • a. No interaction.
  • b. A similar, severe interaction as seen with allopurinol.
  • c. It would decrease azathioprine levels.
  • d. It would cause a mild rash.

Answer: b. A similar, severe interaction as seen with allopurinol.

30. The primary use of azathioprine in GI disorders is for:

  • a. GERD
  • b. Irritable Bowel Syndrome (IBS)
  • c. Inflammatory Bowel Disease (IBD)
  • d. Peptic Ulcer Disease (PUD)

Answer: c. Inflammatory Bowel Disease (IBD)

31. The immunosuppressive effects of azathioprine are mediated by its impact on which cells?

  • a. Red blood cells
  • b. Platelets
  • c. T-lymphocytes and B-lymphocytes
  • d. Neutrophils

Answer: c. T-lymphocytes and B-lymphocytes

32. Can a patient with intermediate TPMT activity be treated with azathioprine?

  • a. No, it is absolutely contraindicated.
  • b. Yes, but typically at a reduced starting dose with careful monitoring.
  • c. Yes, at the standard dose without any changes.
  • d. Yes, but only if they are also taking allopurinol.

Answer: b. Yes, but typically at a reduced starting dose with careful monitoring.

33. Azathioprine is on the NIOSH list of hazardous drugs, requiring careful handling by pharmacy and nursing staff.

  • a. True
  • b. False

Answer: a. True

34. A patient has been stable on azathioprine for 2 years. How often should their CBC be monitored?

  • a. It is no longer necessary.
  • b. Weekly.
  • c. Monthly.
  • d. Every 3-6 months, or per institutional protocol.

Answer: d. Every 3-6 months, or per institutional protocol.

35. A patient on azathioprine should be counseled on the importance of:

  • a. Sun protection, due to an increased risk of skin cancer.
  • b. A high-purine diet.
  • c. Avoiding all vaccinations.
  • d. Taking the medication on an empty stomach.

Answer: a. Sun protection, due to an increased risk of skin cancer.

36. The therapeutic effect of azathioprine relies on its ability to suppress:

  • a. Gastric acid production.
  • b. The inflammatory immune response.
  • c. Peristalsis.
  • d. Histamine release.

Answer: b. The inflammatory immune response.

37. If TPMT testing is not available, a common practice is to:

  • a. Start at the highest possible dose of azathioprine.
  • b. Start at a very low dose and titrate up slowly with frequent CBC monitoring.
  • c. Avoid using azathioprine altogether.
  • d. Use allopurinol concurrently.

Answer: b. Start at a very low dose and titrate up slowly with frequent CBC monitoring.

38. Which of the following drugs can inhibit TPMT activity, potentially increasing the risk of azathioprine toxicity?

  • a. Acetaminophen
  • b. Metformin
  • c. Mesalamine
  • d. Lisinopril

Answer: c. Mesalamine

39. The ultimate goal of azathioprine therapy in IBD is to:

  • a. Cure the disease.
  • b. Provide rapid symptom relief in an acute flare.
  • c. Maintain long-term, steroid-free remission.
  • d. Treat constipation.

Answer: c. Maintain long-term, steroid-free remission.

40. Understanding how prodrugs result in drug action is a key objective in the Medicinal Chemistry curriculum.

  • a. True
  • b. False

Answer: a. True

41. Pancreatitis is a potential, serious idiosyncratic adverse effect of azathioprine.

  • a. True
  • b. False

Answer: a. True

42. A patient calls the pharmacy and says they missed their daily dose of azathioprine this morning. What is the best advice?

  • a. “Take the missed dose now, and take your next dose at the regular time.”
  • b. “Double your dose tomorrow.”
  • c. “Skip today’s dose and resume your normal schedule tomorrow.”
  • d. “Stop taking the medication and call your doctor.”

Answer: c. “Skip today’s dose and resume your normal schedule tomorrow.”

43. Why is routine CBC monitoring essential during the first few months of azathioprine therapy?

  • a. To check for efficacy.
  • b. Because the risk of myelosuppression is highest during initiation.
  • c. To monitor for pancreatitis.
  • d. To check for drug interactions.

Answer: b. Because the risk of myelosuppression is highest during initiation.

44. The conversion of azathioprine to 6-mercaptopurine is what kind of reaction?

  • a. An enzymatic reaction in the liver.
  • b. A non-enzymatic reaction involving glutathione.
  • c. An acid-catalyzed reaction in the stomach.
  • d. A reaction that only occurs in the colon.

Answer: b. A non-enzymatic reaction involving glutathione.

45. A patient should be counseled that they should not receive which type of vaccine while on azathioprine?

  • a. Inactivated vaccines (e.g., standard flu shot)
  • b. Live attenuated vaccines (e.g., MMR, varicella)
  • c. Recombinant vaccines (e.g., Shingrix)
  • d. All vaccines are contraindicated.

Answer: b. Live attenuated vaccines (e.g., MMR, varicella)

46. A decrease in which cell line on a CBC would be the most concerning sign of azathioprine-induced myelosuppression?

  • a. Red blood cells
  • b. Eosinophils
  • c. White blood cells (leukocytes)
  • d. Basophils

Answer: c. White blood cells (leukocytes)

47. The pharmacology of azathioprine is covered under the module for selected anti-inflammatory agents.

  • a. True
  • b. False

Answer: a. True

48. Is azathioprine safe to use during pregnancy for IBD?

  • a. It is absolutely contraindicated.
  • b. It is considered a relatively safe and often necessary option, as the risk of an active IBD flare outweighs the risk of the medication.
  • c. It is only safe in the first trimester.
  • d. It is only safe in the third trimester.

Answer: b. It is considered a relatively safe and often necessary option, as the risk of an active IBD flare outweighs the risk of the medication.

49. If a patient experiences nausea when starting azathioprine, the pharmacist can recommend:

  • a. Discontinuing the medication immediately.
  • b. Taking the medication with food or in divided doses.
  • c. Taking an OTC antiemetic 30 minutes before each dose.
  • d. Both b and c are reasonable recommendations.

Answer: d. Both b and c are reasonable recommendations.

50. The complex pharmacology and pharmacogenomics of azathioprine underscore the pharmacist’s critical role in:

  • a. Dispensing medications quickly.
  • b. Ensuring patient safety through monitoring, education, and drug interaction screening.
  • c. Only managing over-the-counter medications.
  • d. Recommending surgical interventions.

Answer: b. Ensuring patient safety through monitoring, education, and drug interaction screening.

Leave a Comment